Td Ameritrade Investment Management, LLC Seagen Inc. Transaction History

Td Ameritrade Investment Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$191.51 - $216.16 $62,623 - $70,684	-327 Closed	0 $0
Q2 2023 Aug 09, 2023	SELL	$187.64 - $206.25 $76,557 - $84,150	-408 Reduced 55.51%	327 $63,000
Q1 2023 May 15, 2023	SELL	$127.59 - $203.08 $22,838 - $36,351	-179 Reduced 19.58%	735 $149,000
Q4 2022 Feb 09, 2023	SELL	$117.37 - $139.17 $34,741 - $41,194	-296 Reduced 24.46%	914 $117,000
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $15,691 - $20,892	-116 Reduced 8.75%	1,210 $166,000
Q2 2022 Aug 09, 2022	SELL	$108.81 - $179.33 $21,435 - $35,328	-197 Reduced 12.93%	1,326 $235,000
Q1 2022 May 16, 2022	SELL	$119.61 - $157.85 $12,439 - $16,416	-104 Reduced 6.39%	1,523 $219,000
Q4 2021 Feb 11, 2022	BUY	$142.57 - $190.86 $231,961 - $310,529	1,627 New	1,627 $252,000
Q3 2021 Nov 12, 2021	SELL	$142.45 - $169.82 $244,586 - $291,580	-1,717 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$135.08 - $161.1 $62,542 - $74,589	463 Added 36.92%	1,717 $271,000
Q4 2020 Feb 10, 2021	BUY	$164.63 - $211.93 $206,446 - $265,760	1,254 New	1,254 $220,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Td Ameritrade Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Td Ameritrade Investment Management, LLC with notifications on news.